CYP2B6 and neoplasm: Other genes with direct association with tumor, exitus risk and renal clearance (CYP2B6 and ABCC2) also proved interactions with variants in other genes that significantly associated with increased risk of acute rejection, nephrotoxicity (both with ABCB1 variants, which were also proved to alter tacrolimus pharmacokinetics and renal clearance by themselves).